King's College London

Research portal

Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish
Pages (from-to)341-342
Number of pages2
JournalAlimentary Pharmacology and Therapeutics
Volume54
Issue number3
DOIs
PublishedAug 2021

Bibliographical note

Funding Information: Declaration of personal interests: SH has served as a speaker for Pfizer, Janssen and Takeda. Polychronis Pavlidis has received research funding from Galapagos. PI has served as a speaker, and/or a consultant, and/or an advisory board member for Abbvie, Warner Chilcott, Ferring, Falk Pharma, Takeda, MSD, Johnson and Johnson, Shire, Pfizer, Vifor Pharma, Pharmacosmos, Topivert, Genentech, Hospira and Samsung Bioepis, and has received research funding from MSD, Takeda and Pfizer. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

King's Authors

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454